Catalysts / JBIO
Upcoming FDA decisions and readouts we track for Jade Biosciences, each with the filing that announced it.
FreeBioList tracks 3 upcoming catalysts for Jade Biosciences (JBIO, listed on Nasdaq). They cover 3 programmes: JADE301 (Dermatomyositis), JADE101 (IgA nephropathy (APRIL antibody)) and JADE201 (Rheumatoid arthritis).
First on the list: the Phase 1 readout for JADE301 (Dermatomyositis), guided by the company to H2 2027. The furthest-out event tracked is 2027. By stage, the upcoming rows are 2 Phase 1 readouts and 1 Phase 2 readout.
All 3 rows link to SEC filings (8-K or 6-K). All have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Jade Biosciences JBIO · Nasdaq | JADE301 | Dermatomyositis | H2 2027 company guidance |
Phase 1 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Jade Biosciences JBIO · Nasdaq | JADE101 | IgA nephropathy (APRIL antibody) | 2027 company guidance |
Phase 2 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Jade Biosciences JBIO · Nasdaq | JADE201 | Rheumatoid arthritis | 2027 company guidance |
Phase 1 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList